Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities

Kalachnik, John E.

doi:10.1002/(sici)1098-2779(1999)5:4<348::aid-mrdd13>3.0.co;2-n

Cited by 29 publications

(21 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 The Dyskinesia Identification System Condensed User Scale is a tool for assessing tardive dyskinesia that was developed and normed for people with developmental disabilities. 72 Tics are another potential side effect in subjects with ASDs, and tic scales may be of special relevance in trials of stimulants and related agents.…”

Section: What Side Effect Scale To Use?mentioning

confidence: 99%

Outcome Measures for Clinical Drug Trials in Autism

Aman¹,

Novotny²,

Samango‐Sprouse³

et al. 2004

CNS spectr.

View full text Add to dashboard Cite

This paper identifies instruments and measures that may be appropriate for randomized clinical trials in participants with autism spectrum disorders (ASDs HHS Public Access Author Manuscript Author ManuscriptAuthor Manuscript Author Manuscript scale was recommended for all randomized clinical trials. At this point, however, there is no "perfect" choice of outcome measure for core features of autism, although we will discuss five measures of potential utility. Several communication instruments are recommended, based in part on suitability across the age range. In trials where the intention is to alter core features of ASDs, adaptive behavior scales are also worthy of consideration. Several "behavior complexes" common to ASDs are identified, and instruments are recommended for assessment of these. Given the prevalence of cognitive impairment in ASDs, it is important to assess any cognitive effects, although cognitive data from ASD randomized clinical trials, thus far, are minimal. Guidance from trials in related pharmacologic areas and behavioral pharmacology may be helpful. We recommend routine elicitation of side effects, height and weight, vital signs, and (in the case of antipsychotics) extrapyramidal side-effects assessment. It is often appropriate to include laboratory tests and assessments for continence and sleep pattern.

show abstract

Section: What Side Effect Scale To Use?mentioning

confidence: 99%

Outcome Measures for Clinical Drug Trials in Autism

Aman¹,

Novotny²,

Samango‐Sprouse³

et al. 2004

CNS spectr.

View full text Add to dashboard Cite

show abstract

“…The UKU-SERS-ID seems to be easy to use and clinically meaningful. Other tools developed for this purpose (Kalachnik, 1999;Matson et al, 2000) seem too large and complex to use in an everyday clinical setting (Tveter et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Short communication: reliability and validity of the UKU Side Effect Rating Scale for adults with intellectual disabilities

Tveter

Bakken

Røssberg

et al. 2016

Advances in Mental Health and Intellectual Disabilities

View full text Add to dashboard Cite

About Emerald www.emeraldinsight.comEmerald is a global publisher linking research and practice to the benefit of society. The company manages a portfolio of more than 290 journals and over 2,350 books and book series volumes, as well as providing an extensive range of online products and additional customer resources and services.Emerald is both COUNTER 4 and TRANSFER compliant. The organization is a partner of the Committee on Publication Ethics (COPE) and also works with Portico and the LOCKSS initiative for digital archive preservation. AbstractPurpose -The UKU side effect rating scale for adults with intellectual disabilities (UKU-SERS-ID) was developed to detect side effects among patients with intellectual disabilities (ID). The purpose of this paper is to examine the reliability and face validity of the UKU-SERS-ID. Design/methodology/approach -UKU-SERS-ID comprises 35 items. In total, 22 patients with ID were included from two specialized services for adults with ID and comorbid mental illness. All patients were rated on three different occasions by three clinicians; two nurses and one medical doctor. Reliability was estimated with Cohen's κ. A focus group discussed the face validity of the items comprising the UKU-SERS-ID. Findings -Respectively ten (nurse-nurse scores) and eight (nurse-doctor scores) items were considered difficult to score due to low prevalence of the symptoms. For the other items the reliability was acceptable. Through discussion in a focus group, with the reliability scores in mind, only one of the items of the UKU-SERS-ID was discarded. Practical implications -The authors have developed a feasible side effect instrument for clinical practice. It is easy to score and relevant regarding important side effects. Originality/value -The UKU-SERS-ID seems to be a feasible tool. Further investigations are mandatory in order to gain knowledge about distribution and phenomenology of side effects from psychotropic medication for individuals with ID.

show abstract

“…It is often critical to measure the biological effects of medication given that most people with ID have difficulty answering direct questions about a medication's behavioural and side effects (Kalachnik 1999; Arscott et al . 2000).…”

Section: Methods For Measuring Medication Effectsmentioning

confidence: 99%

Measurement of problem behaviour during medication evaluations

Zarcone

Valdovinos

2008

J intellect Disabil Res

View full text Add to dashboard Cite

Background The focus of this review is on methods that are currently being used to evaluate the behavioural effects of medication for individuals with intellectual disabilities. First we describe what has been identified as the ideal criteria for conducting clinical trials and how these criteria may be adapted to do less controlled evaluations. The central theme is a review of the biological measures (e.g. labs, drug levels), behavioural rating scales and direct observation measures that are often used to evaluate medication effects. Issues related to how the side effects of medication can affect behaviour will also be discussed. Conclusion The importance of encouraging communication and collaboration across all systems of care and the use of socially valid measures are discussed.

show abstract

Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities

Cited by 29 publications

References 61 publications

Outcome Measures for Clinical Drug Trials in Autism

Outcome Measures for Clinical Drug Trials in Autism

Short communication: reliability and validity of the UKU Side Effect Rating Scale for adults with intellectual disabilities

Measurement of problem behaviour during medication evaluations

Contact Info

Product

Resources

About